Somatic mutations in PI3Kα: Structural basis for enzyme activation and drug design

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1804, Issue 3, 2010, Pages 533-540

  Gabelli, Sandra B ^a   Mandelker, Diana ^b   Schmidt Kittler, Oleg ^b   Vogelstein, Bert ^b   Amzel, L Mario ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Gain of function; H1047R mutant; p110 p85; PI3K; Somatic mutation

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; CAL 101; HYDROGEN SULFITE REDUCTASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE; PROTEIN P110; UNCLASSIFIED DRUG; WORTMANNIN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; ISOENZYME;

BINDING SITE; CELL GROWTH; CELL METABOLISM; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; DRUG DESIGN; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVATION; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; INFLAMMATION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SOMATIC MUTATION; ANIMAL; CELL MOTION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASM; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; ISOENZYMES; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 75349088737     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2009.11.020     Document Type: Review

References (53)

1. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
2. Vanhaesebroeck B., Higashi K., Raven C., Welham M., Anderson S., Brennan P., Ward S.G., and Waterfield M.D. Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. Embo J. 18 (1999) 1292-1302
3. Marone R., Cmiljanovic V., Giese B., and Wymann M.P. Targeting phosphoinositide 3-kinase-Moving towards therapy. Biochim. Biophys. Acta 1784 (2008) 159-185
4. Vanhaesebroeck B., and Alessi D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346 Pt. 3 (2000) 561-576
5. Vanhaesebroeck B., and Waterfield M.D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. 253 (1999) 239-254
6. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., and Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17 (2001) 615-675
7. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
8. Carson J.D., Van Aller G., Lehr R., Sinnamon R.H., Kirkpatrick R.B., Auger K.R., Dhanak D., Copeland R.A., Gontarek R.R., Tummino P.J., and Luo L. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem. J. 409 (2008) 519-524
9. Gymnopoulos M., Elsliger M.A., and Vogt P.K. Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 5569-5574
10. http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=bygene&ln=PIK3CA&start=1&end=1069&coords=AA:AA.
11. Zhao L., and Vogt P.K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 2652-2657
12. Catasus L., Gallardo A., Cuatrecasas M., and Prat J. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod. Pathol. 21 (2008) 131-139
13. Kalinsky K., Jacks L.M., Heguy A., Patil S., Drobnjak M., Bhanot U.K., Hedvat C.V., Traina T.A., Solit D., Gerald W., and Moynahan M.E. PIK3CA mutation associates with improved outcome in breast cancer. Clin. Cancer Res. 15 (2009) 5049-5059
14. Lai Y., Mau B., Cheng W., Chen H., Chiu H., and Tzen C. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann. Surg. Oncol. 15 (2008) 1064-1069
15. Lerma E., Catasus L., Gallardo A., Peiro G., Alonso C., Aranda I., Barnadas A., and Prat J. Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows. Arch. 453 (2008) 133-139
16. Marone R., Erhart D., Mertz A.C., Bohnacker T., Schnell C., Cmiljanovic V., Stauffer F., Garcia-Echeverria C., Giese B., Maira S.M., and Wymann M.P. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol. Cancer Res. 7 (2009) 601-613
17. Guillermet-Guibert J., Bjorklof K., Salpekar A., Gonella C., Ramadani F., Bilancio A., Meek S., Smith A.J., Okkenhaug K., and Vanhaesebroeck B. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 8292-8297
18. Musacchio A., Cantley L.C., and Harrison S.C. Crystal structure of the breakpoint cluster region-homology domain from phosphoinositide 3-kinase p85 alpha subunit. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14373-14378
19. Booker G.W., Breeze A.L., Downing A.K., Panayotou G., Gout I., Waterfield M.D., and Campbell I.D. Structure of an SH2 domain of the p85 alpha subunit of phosphatidylinositol-3-OH kinase. Nature 358 (1992) 684-687
20. Nolte R., Eck M., Schlessinger J., Shoelson S., and Harrison S. Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes. Nat. Struct. Biol. 3 (1996) 364-374
21. Pauptit R.A., Dennis C.A., Derbyshire D.J., Breeze A.L., Weston S.A., Rowsell S., and Murshudov G.N. NMR trial models: experiences with the colicin immunity protein Im7 and the p85alpha C-terminal SH2-peptide complex. Acta Crystallogr. D Biol. Crystallogr. 57 (2001) 1397-1404
22. Walker E.H., Perisic O., Ried C., Stephens L., and Williams R.L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402 (1999) 313-320
23. Huang C.H., Mandelker D., Schmidt-Kittler O., Samuels Y., Velculescu V.E., Kinzler K.W., Vogelstein B., Gabelli S.B., and Amzel L.M. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318 (2007) 1744-1748
24. Mandelker D., Gabelli S., Schmidt-Kittler O., Zhu J., Huang C., Kinsler K., Vogelstein B., and Amzel L. A frequent kinase domain mutation that changes the interaction between PI3Ka and the membrane. Proc. Natl. Acad. Sci. U. S. A. 106 40 (2009) 16996-17001
25. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
26. Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., and Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3 (1999) 639-648
27. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., Balla T., Weiss W.A., Williams R.L., and Shokat K.M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125 (2006) 733-747
28. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., and Garcia-Echeverria C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7 (2008) 1851-1863
29. Pirola L., Zvelebil M.J., Bulgarelli-Leva G., Van Obberghen E., Waterfield M.D., and Wymann M.P. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha). Functions of lipid kinase-deficient PI3Kalpha in signaling. J. Biol. Chem. 276 (2001) 21544-21554
30. Miled N., Yan Y., Hon W.C., Perisic O., Zvelebil M., Inbar Y., Schneidman-Duhovny D., Wolfson H.J., Backer J.M., and Williams R.L. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317 (2007) 239-242
31. Mankoo P.K., Sukumar S., and Karchin R. PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations. Proteins 75 (2009) 499-508
32. Williams R., Berndt A., Miller S., Hon W.C., and Zhang X. Form and flexibility in phosphoinositide 3-kinases. Biochem. Soc. Trans. 37 (2009) 615-626
33. Cancer G.A.R. Network, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
34. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz Jr. L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., and Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
35. Norman B.H., Shih C., Toth J.E., Ray J.E., Dodge J.A., Johnson D.W., Rutherford P.G., Schultz R.M., Worzalla J.F., and Vlahos C.J. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J. Med. Chem. 39 (1996) 1106-1111
36. Wipf P., Minion D.J., Halter R.J., Berggren M.I., Ho C.B., Chiang G.G., Kirkpatrick L., Abraham R., and Powis G. Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. Org. Biomol. Chem. 2 (2004) 1911-1920
37. Vlahos C.J., Matter W.F., Hui K.Y., and Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269 (1994) 5241-5248
38. Ihle N.T., Williams R., Chow S., Chew W., Berggren M.I., Paine-Murrieta G., Minion D.J., Halter R.J., Wipf P., Abraham R., Kirkpatrick L., and Powis G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 3 (2004) 763-772
39. Garlich J.R., De P., Dey N., Su J.D., Peng X., Miller A., Murali R., Lu Y., Mills G.B., Kundra V., Shu H.K., Peng Q., and Durden D.L. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 68 (2008) 206-215
40. Camps M., Ruckle T., Ji H., Ardissone V., Rintelen F., Shaw J., Ferrandi C., Chabert C., Gillieron C., Francon B., Martin T., Gretener D., Perrin D., Leroy D., Vitte P.A., Hirsch E., Wymann M.P., Cirillo R., Schwarz M.K., and Rommel C. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11 (2005) 936-943
41. Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., and Williams R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6 (2000) 909-919
42. Amzel L.M., Huang C.H., Mandelker D., Lengauer C., Gabelli S.B., and Vogelstein B. Structural comparisons of class I phosphoinositide 3-kinases. Nat. Rev. Cancer 8 (2008) 665-669
43. Booker G.W., Gout I., Downing A.K., Driscoll P.C., Boyd J., Waterfield M.D., and Campbell I.D. Solution structure and ligand-binding site of the SH3 domain of the p85 alpha subunit of phosphatidylinositol 3-kinase. Cell 73 (1993) 813-822
44. Gunther U.L., Weyrauch B., Zhang X., and Schaffhausen B. Nuclear magnetic resonance structure of the P395S mutant of the N-SH2 domain of the p85 subunit of PI3 kinase: an SH2 domain with altered specificity. Biochemistry 42 (2003) 11120-11127
45. Hoedemaeker F.J., Siegal G., Roe S.M., Driscoll P.C., and Abrahams J.P. Crystal structure of the C-terminal SH2 domain of the p85alpha regulatory subunit of phosphoinositide 3-kinase: an SH2 domain mimicking its own substrate. J. Mol. Biol. 292 (1999) 763-770
46. Siegal G., Davis B., Kristensen S.M., Sankar A., Linacre J., Stein R.C., Panayotou G., Waterfield M.D., and Driscoll P.C. Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase. J. Mol. Biol. 276 (1998) 461-478
47. Breeze A.L., Kara B.V., Barratt D.G., Anderson M., Smith J.C., Luke R.W., Best J.R., and Cartlidge S.A. Structure of a specific peptide complex of the carboxy-terminal SH2 domain from the p85 alpha subunit of phosphatidylinositol 3-kinase. EMBO J. 15 (1996) 3579-3589
48. Apsel B., Blair J.A., Gonzalez B., Nazif T.M., Feldman M.E., Aizenstein B., Hoffman R., Williams R.L., Shokat K.M., and Knight Z.A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4 (2008) 691-699
49. Folkes A.J., Ahmadi K., Alderton W.K., Alix S., Baker S.J., Box G., Chuckowree I.S., Clarke P.A., Depledge P., Eccles S.A., Friedman L.S., Hayes A., Hancox T.C., Kugendradas A., Lensun L., Moore P., Olivero A.G., Pang J., Patel S., Pergl-Wilson G.H., Raynaud F.I., Robson A., Saghir N., Salphati L., Sohal S., Ultsch M.H., Valenti M., Wallweber H.J., Wan N.C., Wiesmann C., Workman P., Zhyvoloup A., Zvelebil M.J., and Shuttleworth S.J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51 (2008) 5522-5532
50. Pacold M.E., Suire S., Perisic O., Lara-Gonzalez S., Davis C.T., Walker E.H., Hawkins P.T., Stephens L., Eccleston J.F., and Williams R.L. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103 (2000) 931-943
51. Perry B., Alexander R., Bennett G., Buckley G., Ceska T., Crabbe T., Dale V., Gowers L., Horsley H., James L., Jenkins K., Crepy K., Kulisa C., Lightfoot H., Lock C., Mack S., Morgan T., Nicolas A.L., Pitt W., Sabin V., and Wright S. Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines. Bioorg. Med. Chem. Lett. 18 (2008) 4700-4704
52. Xie P., Williams D.S., Atilla-Gokcumen G.E., Milk L., Xiao M., Smalley K.S., Herlyn M., Meggers E., and Marmorstein R. Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem. Biol. 3 (2008) 305-316
53. Zask A., Verheijen J.C., Curran K., Kaplan J., Richard D.J., Nowak P., Malwitz D.J., Brooijmans N., Bard J., Svenson K., Lucas J., Toral-Barza L., Zhang W.G., Hollander I., Gibbons J.J., Abraham R.T., Ayral-Kaloustian S., Mansour T.S., and Yu K. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. J. Med. Chem. 52 (2009) 5013-5016